Eli Lilly and Company (NYSE:LLY) Shares Acquired by Live Oak Private Wealth LLC

02 Jan 2024, 17:14 by Michael Walen · The Markets Daily

Live Oak Private Wealth LLC increased its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 2.3% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,809 shares of the company’s stock after buying an additional 40 shares during the quarter. Live Oak Private Wealth LLC’s holdings in Eli Lilly and Company were worth $972,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Retirement Group LLC lifted its stake in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares in the last quarter. Cornerstone Planning Group LLC acquired a new position in Eli Lilly and Company in the 2nd quarter worth about $33,000. Raleigh Capital Management Inc. increased its position in Eli Lilly and Company by 156.4% in the 1st quarter. Raleigh Capital Management Inc. now owns 100 shares of the company’s stock worth $34,000 after purchasing an additional 61 shares during the last quarter. Activest Wealth Management acquired a new position in Eli Lilly and Company in the 2nd quarter worth about $40,000. Finally, RVW Wealth LLC acquired a new position in Eli Lilly and Company in the 3rd quarter worth about $46,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 670 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $571.10, for a total value of $382,637.00. Following the sale, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 670 shares of the stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $571.10, for a total transaction of $382,637.00. Following the sale, the chief accounting officer now owns 4,708 shares of the company’s stock, valued at approximately $2,688,738.80. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 215,000 shares of the stock in a transaction dated Wednesday, October 11th. The stock was sold at an average price of $605.44, for a total transaction of $130,169,600.00. Following the sale, the insider now directly owns 99,768,810 shares in the company, valued at approximately $60,404,028,326.40. The disclosure for this sale can be found here. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Trading Up 0.4 %

Shares of Eli Lilly and Company stock opened at $582.92 on Tuesday. Eli Lilly and Company has a 52-week low of $309.20 and a 52-week high of $629.97. The firm has a market capitalization of $553.37 billion, a PE ratio of 105.60, a price-to-earnings-growth ratio of 3.55 and a beta of 0.31. The company has a debt-to-equity ratio of 1.59, a current ratio of 1.05 and a quick ratio of 0.82. The company’s fifty day moving average price is $585.27 and its two-hundred day moving average price is $542.48.

Eli Lilly and Company (NYSE:LLY – Get Free Report) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The company had revenue of $9.50 billion during the quarter, compared to analysts’ expectations of $8.88 billion. On average, analysts expect that Eli Lilly and Company will post 6.6 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 4th. Stockholders of record on Thursday, February 15th will be issued a $1.30 dividend. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.13. The ex-dividend date is Wednesday, February 14th. This represents a $5.20 annualized dividend and a dividend yield of 0.89%. Eli Lilly and Company’s dividend payout ratio is presently 81.88%.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research reports. Citigroup upped their target price on Eli Lilly and Company from $525.00 to $675.00 and gave the stock a “buy” rating in a research report on Monday, October 23rd. Argus upped their target price on Eli Lilly and Company from $470.00 to $620.00 and gave the stock a “buy” rating in a research report on Tuesday, September 5th. Morgan Stanley increased their price objective on Eli Lilly and Company from $727.00 to $822.00 and gave the company an “overweight” rating in a report on Tuesday, December 19th. Truist Financial reissued a “buy” rating and set a $650.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, November 29th. Finally, Wells Fargo & Company increased their price objective on Eli Lilly and Company from $615.00 to $650.00 and gave the company an “overweight” rating in a report on Monday, October 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $583.24.

View Our Latest Report on Eli Lilly and Company

Eli Lilly and Company Company Profile

(Free Report)